Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance

Guo, Charles C.; Epstein, Jonathan I.

doi:10.1038/modpathol.3800702

Cited by 304 publications

(432 citation statements)

References 12 publications

Supporting

Mentioning

419

Contrasting

Unclassified

Order By: Relevance

“…Their criteria defined intraductal carcinoma of the prostate as malignant epithelial cells filling large acini and prostatic ducts with preservation of basal cells and a solid or dense cribriform pattern or a loose cribriform or micropapillary pattern with either marked nuclear atypia with a nuclear size six times the normal or nonfocal comedonecrosis. 5 Immunohistochemical stain for p63 was used to confirm retention of the basal layer in cases histologically consistent with intraductal carcinoma of the prostate. After the diagnosis of intraductal carcinoma of the prostate was confirmed, an immunohistochemical stain for the ERG protein was performed on all cases as follows: formalinfixed, paraffin-embedded prostate tissue from the various specimens was sectioned at 4 mm.…”

Section: Methodsmentioning

confidence: 99%

ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma

Schneider

Osunkoya

2014

Modern Pathology

View full text Add to dashboard Cite

Intraductal carcinoma of the prostate is a growth pattern of prostatic adenocarcinoma that has not been well characterized from the molecular standpoint. It remains debatable whether intraductal carcinoma of the prostate represents colonization of benign glands by pre-existing conventional prostatic adenocarcinoma, or progression of high-grade prostatic intraepithelial neoplasia. TMPRSS2-ERG is the most common gene fusion in conventional prostatic adenocarcinoma, identified in about 40-70% of cases. In this study, we compared the expression of ERG in intraductal carcinoma of the prostate and adjacent conventional prostatic adenocarcinoma. Thirty-one confirmed cases of intraductal carcinoma of the prostate, with adjacent conventional prostatic adenocarcinoma and available tissue blocks, were identified at our institution. Immunohistochemical stains were performed for ERG using a rabbit anti-ERG monoclonal antibody. The ERG expression in the intraductal carcinoma of the prostate component was compared with that in the adjacent conventional prostatic adenocarcinoma. Mean patient age was 65 years (range: 48-79 years). Positive ERG expression was identified in 11/31 (35%) cases of intraductal carcinoma of the prostate. In all 11/11 (100%) cases with positive ERG expression in the intraductal carcinoma of the prostate component, ERG expression was also positive in the adjacent conventional prostatic adenocarcinoma. In the 20/31 cases with negative ERG expression in the intraductal carcinoma of the prostate component, ERG was also negative in the adjacent conventional prostatic adenocarcinoma. It is highly conceivable that based on the identical ERG expression (positive or negative) in intraductal carcinoma of the prostate and the adjacent conventional prostatic adenocarcinoma, intraductal carcinoma of the prostate most likely represents colonization of benign glands by adjacent pre-existing conventional prostatic adenocarcinoma.

show abstract

Section: Methodsmentioning

confidence: 99%

ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma

Schneider

Osunkoya

2014

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…This term has been used for several decades, dating back to at least 1985 [2], and it has been variably used to describe intraductal spread or in situ E U R O P E A N U R O L O G Y X X X ( 2 0 1 6 ) X X X -X X X growth of acinar or ductal adenocarcinoma of the prostate and intraductal proliferation of urothelial carcinoma [3][4][5][6][7][8][9][10][11]. The 2016 WHO definition is as follows: ''Intraductal carcinoma of the prostate is intra-acinar and/or intraductal neoplastic epithelial proliferation that has some features of high-grade prostatic intraepithelial neoplasia (HGPIN) but exhibits much greater architectural and/or cytological atypia, typically associated with high-grade, high-stage prostate carcinoma.''…”

Section: New Entity: Intraductal Carcinomamentioning

confidence: 99%

“…Intraductal carcinoma is rare in isolated form in needle biopsy tissue, being detected in 0.1-0.3% of needle core cases [11,89], and is uncommon in the presence of invasive adenocarcinoma in needle core tissue, being diagnosed in 2.8% of such cases [11]. In whole prostate glands, the incidence is dependent on the grade and stage of the prostatic adenocarcinoma in the series and ranges from 20% to 40% of RP cases [5,10].…”

Section: New Entity: Intraductal Carcinomamentioning

confidence: 99%

“…In contrast to HGPIN, intraductal carcinoma exhibits a solid or dense cribriform pattern or a loose cribriform or micropapillary pattern with either marked nuclear atypia (ie, nuclear size !6Â normal) or comedonecrosis ( Fig. 2) [11]. PTEN and ERG immunostaining may be a useful adjunctive method because intraductal carcinoma commonly shows PTEN loss and ERG expression, whereas PTEN loss is rare in HGPIN and ERG expression is uncommon [12].…”

Section: New Entity: Intraductal Carcinomamentioning

confidence: 99%

“…FGFR3 mutations, for example, are seen in up to 80% of papillary noninvasive and low-grade carcinomas. Although these mutations have been associated with a higher risk of recurrence, they are not associated with disease progression [11,127]. Mutations in chromatin-remodelling and histonemodifying genes have been described in up to 89% of muscularis propria invasive bladder tumours [116,128].…”

Section: Genomics Of Urothelial Carcinomamentioning

confidence: 99%

See 2 more Smart Citations

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

et al. 2016

View full text Add to dashboard Cite

It has been 12 yr since the publication of the last World Health Organization (WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours. Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 WHO classification. In most cases, it represents intraductal spread of aggressive prostatic carcinoma and should be separated from high-grade prostatic intraepithelial neoplasia. New acinar adenocarcinoma variants are microcystic adenocarcinoma and pleomorphic giant cell adenocarcinoma. Modifications to the Gleason grading system are incorporated into the 2016 WHO section on grading of prostate cancer, and it is recommended that the percentage of pattern 4 should be reported for Gleason score 7. The new WHO classification further recommends the recently developed prostate cancer grade grouping with five grade groups. For bladder cancer, the 2016 WHO classification continues to recommend the 1997 International Society of Urological Pathology grading classification. Newly described or better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential, which is frequently identified in patients with a prior history of urothelial carcinoma. Invasive urothelial carcinoma with divergent differentiation refers to tumours with some percentage of "usual type" urothelial carcinoma combined with other morphologies. Pathologists should mention the percentage of divergent histologies in the pathology report. PATIENT SUMMARY Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 World Health Organization classification. Better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential. v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j AbstractIt has been 12 yr since the publication of the last World Health Organization (WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours.

show abstract

Cribriform pattern in prostate tissues: Predictor for intraductal carcinoma of the prostate based on biopsy and radical prostatectomy pathology

et al. 2022

View full text Add to dashboard Cite

Objectives: This study aims to investigate whether a cribriform pattern on prostate biopsy may be a factor in suspicion of intraductal carcinoma of the prostate after radical prostatectomy.Methods: This retrospective study assessed 100 men who underwent prostatectomy from 2015 to 2019. Participants were grouped as 76 patients with Gleason pattern 4 and 24 patients without this pattern. All 100 participants underwent retrograde radical prostatectomy and limited lymph node dissection. The same pathologist evaluated all specimens. The cribriform pattern was evaluated with haematoxylin and eosin counterstaining, and intraductal carcinoma of the prostate was evaluated with immunohistochemical analysis of cytokeratin 34βE12.Results: Patients with intraductal carcinoma of the prostate on immunohistochemical analysis showed a significant tendency to relapse in the postoperative period, and those with the cribriform pattern on biopsy had a significant recurrence rate. In univariate and multivariate analyses, intraductal carcinoma of the prostate confirmed in biopsy tissue was an independent predictor of biochemical recurrence after prostatectomy. The rate of intraductal carcinoma of the prostate confirmation was 28% of cases with a cribriform pattern in biopsy tissue, which was increased to 62% in prostatectomy tissues. Conclusion:The cribriform pattern in the biopsy tissue may be a predictor for intraductal carcinoma of the prostate.

show abstract

Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance

Cited by 304 publications

References 12 publications

ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma

ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

Cribriform pattern in prostate tissues: Predictor for intraductal carcinoma of the prostate based on biopsy and radical prostatectomy pathology

Contact Info

Product

Resources

About